SlideShare ist ein Scribd-Unternehmen logo
1 von 61
Guideline Summary Updated US Public Health Service Guidelines for the Management of Occupational  Exposures to HIV and Recommendations  for Postexposure Prophylaxis
Guidelines for the Management of Occupational Exposures to HIV and Recommendations for Postexposure Prophylaxis   Developed by the Public Health Service Interagency Working Group, convened by National Center for Infectious Diseases, CDC
Guidelines Outline ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Guidelines Outline  (2) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
What the Guidelines Address ,[object Object],[object Object],[object Object],[object Object],Continued
What the Guidelines Address  (2) ,[object Object],[object Object],[object Object],[object Object]
What the Guidelines DO NOT Address ,[object Object],[object Object],[object Object]
Websites to Access the Guidelines ,[object Object],[object Object],Websites to Access NY AIDS Inst Guidelines   http://www.hivguidelines.org/GuideLine.aspx?pageID=78&guideLineID=3 http://www.wnysmart.org/Documents/EM/pep_card.pdf
PEP after Occupational Exposure http://www.hivguidelines.org/GuideLine.aspx?pageID=78&guideLineID=3
Recommendation: recording information following occupational exposure ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Occupational Risk Exposures in Health Care Personnel ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
NOT Considered Infectious for HIV, unless  Visibly Bloody ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Risk of HIV Infection following Occupational Exposure to HIV-Infected Blood ,[object Object],[object Object],[object Object]
 
Factors Associated with Increased Risk ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
GENERAL MANAGEMENT CONSIDERATIONS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Exposures for which PEP is Indicated ,[object Object],[object Object],[object Object],[object Object]
Toxicity of PEP Regimens ,[object Object],[object Object],[object Object]
Interactions of ARV Agents ,[object Object],[object Object],[object Object],[object Object]
Resistance to ARVs ,[object Object],[object Object],[object Object],[object Object]
IMPLEMENTING PEP  ,[object Object],[object Object],[object Object],[object Object]
Planning for PEP ,[object Object],[object Object],[object Object],[object Object],[object Object]
PEP considerations (cont’d) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Initiating PEP ,[object Object],[object Object],[object Object]
Initiating PEP  (2) ,[object Object],[object Object],[object Object]
Selecting the PEP Regimen ,[object Object],[object Object],[object Object]
NY AIDS inst recommended PEP www.hivguidelines.org
MONITORING THE HCW FOLLOWING OCCUPATIONAL EXPOSURE ,[object Object],[object Object],[object Object],[object Object],[object Object]
 
Follow-Up of Exposed HCP ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
PEP FOR THE PREGNANT HCW   ,[object Object],[object Object],[object Object],[object Object],[object Object]
 
Situations for Which Expert Consultation Is Advised  (4) ,[object Object],[object Object],[object Object],[object Object]
Follow-Up of Exposed HCP  (2) ,[object Object]
Follow-Up of Exposed HCP  (3) ,[object Object]
Follow-Up of Exposed HCP  (4) ,[object Object],[object Object],[object Object],[object Object],[object Object]
Follow-Up of Exposed HCP  (5) ,[object Object]
Follow-Up of Exposed HCP  (6) ,[object Object],[object Object],[object Object],[object Object],[object Object]
OCCUPATIONAL PEP FOR HBV & HCV ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],HBV, HCV post-expos considerations
 
How Many Drugs to Use? ,[object Object],[object Object],[object Object]
How Many Drugs to Use?  (2) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
PEP for Percutaneous Injuries Exposure Type Infection Status of Source Recommend expanded  ≥ 3-drug PEP Recommend expanded 3-drug PEP More severe Recommend expanded  ≥ 3-drug PEP Recommend basic 2-drug PEP Less severe HIV+, class 2 HIV+, class 1
PEP for Percutaneous Injuries  (2)   Exposure Type Infection Status of Source *If PEP is given and source is later determined to be HIV negative, PEP should be discontinued. As above Generally, no PEP warranted; consider basic 2-drug PEP if exposure to HIV-infected persons is likely Unknown source As above More severe Generally, no PEP warranted; consider basic 2-drug PEP if source has HIV risk factors Less severe Unknown HIV status*
PEP for Percutaneous Injuries  (3)   Exposure Type Infection Status of Source No PEP More severe No PEP Less severe HIV negative
PEP for Mucous Membrane and Nonintact Skin Exposures Exposure Type Infection Status of Source Recommend expanded  ≥ 3-drug PEP Recommend basic 2-drug PEP More severe Recommend basic 2-drug PEP Consider basic 2-drug PEP Less severe HIV+, class 2 HIV+, class 1
PEP for Mucous Membrane and Nonintact Skin Exposures  (2) Exposure Type Infection Status of Source *If source is determined to be HIV negative after PEP is initiated, discontinue PEP. Generally, no PEP warranted; consider basic 2-drug PEP if exposure to HIV-infected persons is likely Generally, no PEP warranted Unknown source Generally, no PEP warranted; consider basic 2-drug PEP if source has HIV risk factors More severe Generally, no PEP warranted Less severe Unknown HIV status*
PEP for Mucous Membrane and Nonintact Skin Exposures  (3) Exposure Type Infection Status of Source No PEP More severe No PEP Less severe HIV negative
Which Drugs to Use? ,[object Object],[object Object],[object Object]
Which Drugs to Use?  (2) ,[object Object],[object Object]
Which Drugs to Use?  (3) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Which Drugs to Use?  (4) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],+  basic 2-drug regimen * If ATV is coadmnistered with TDF, RTV must be included in the PEP regimen. ** Avoid in late pregnancy.  *** Avoid in pregnancy.
Which Drugs to Use?  (5) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Selection of  Drugs for PEP: Consultation Is Part of the Guidelines ,[object Object]
Resources for Consultation ,[object Object],[object Object],[object Object]
Situations for Which Expert Consultation Is Advised ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Continued
Situations for Which Expert Consultation Is Advised  (2) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Continued
Situations for Which Expert Consultation Is Advised  (3) ,[object Object],[object Object],[object Object],[object Object],[object Object]
About This Slide Set ,[object Object],[object Object]
About This Presentation These slides were developed using the September 2005 guidelines on postexposure prophylaxis (PEP) following occupational exposure to HIV. The intended audience is clinicians involved in the care of health care personnel (HCP) with occupational exposure to HIV.  Users are cautioned that, because of the rapidly changing field of HIV care, this information could become out of date quickly. Finally, it is intended that these slides be used as prepared, without changes in either content or attribution. Users are asked to honor this intent. –  AETC NRC http://www.aidsetc.org

Weitere ähnliche Inhalte

Was ist angesagt?

Revisedpart iiipme lecture 2012presentationpart3
Revisedpart iiipme lecture 2012presentationpart3Revisedpart iiipme lecture 2012presentationpart3
Revisedpart iiipme lecture 2012presentationpart3University of Miami
 
Breakthrough Designation Opportunities Challenges AAPS 2014
Breakthrough Designation Opportunities Challenges AAPS 2014Breakthrough Designation Opportunities Challenges AAPS 2014
Breakthrough Designation Opportunities Challenges AAPS 2014Ajaz Hussain
 
Pace study training slides 22 09-2015 v2.1
Pace study training slides 22 09-2015 v2.1Pace study training slides 22 09-2015 v2.1
Pace study training slides 22 09-2015 v2.1angewatkins
 
Module 4 monitoring v2
Module 4 monitoring v2Module 4 monitoring v2
Module 4 monitoring v2OlgaPaterson1
 
The berlin patient
The berlin patientThe berlin patient
The berlin patientAdrizaBera
 
The difference between practice and research 111607
The difference between practice and research 111607The difference between practice and research 111607
The difference between practice and research 111607Lanka Praneeth
 
Module 1a n cov introduction v2
Module 1a  n cov introduction v2Module 1a  n cov introduction v2
Module 1a n cov introduction v2OlgaPaterson1
 
Safe Injection Practices (AD Roman) - PHICS 2019
Safe Injection Practices (AD Roman) - PHICS 2019Safe Injection Practices (AD Roman) - PHICS 2019
Safe Injection Practices (AD Roman) - PHICS 2019Arthur Dessi Roman
 
Operational research to increase the efficiency of ART initiation in Africa
Operational research to increase the efficiency of ART initiation in AfricaOperational research to increase the efficiency of ART initiation in Africa
Operational research to increase the efficiency of ART initiation in AfricaSydney Rosen
 
Annual ed core measures.09 10
Annual ed core measures.09 10Annual ed core measures.09 10
Annual ed core measures.09 10capstonerx
 
Patient safety and error reduction approaches
Patient safety and error reduction approachesPatient safety and error reduction approaches
Patient safety and error reduction approachesLallu Joseph
 
Role of infection control in patient safety [compatibility mode]
Role of infection control in patient safety [compatibility mode]Role of infection control in patient safety [compatibility mode]
Role of infection control in patient safety [compatibility mode]drnahla
 

Was ist angesagt? (20)

Revisedpart iiipme lecture 2012presentationpart3
Revisedpart iiipme lecture 2012presentationpart3Revisedpart iiipme lecture 2012presentationpart3
Revisedpart iiipme lecture 2012presentationpart3
 
Breakthrough Designation Opportunities Challenges AAPS 2014
Breakthrough Designation Opportunities Challenges AAPS 2014Breakthrough Designation Opportunities Challenges AAPS 2014
Breakthrough Designation Opportunities Challenges AAPS 2014
 
Pace study training slides 22 09-2015 v2.1
Pace study training slides 22 09-2015 v2.1Pace study training slides 22 09-2015 v2.1
Pace study training slides 22 09-2015 v2.1
 
Module 4 monitoring v2
Module 4 monitoring v2Module 4 monitoring v2
Module 4 monitoring v2
 
roles and responsibilities of Investigator[663]
roles and responsibilities of Investigator[663]roles and responsibilities of Investigator[663]
roles and responsibilities of Investigator[663]
 
The berlin patient
The berlin patientThe berlin patient
The berlin patient
 
The difference between practice and research 111607
The difference between practice and research 111607The difference between practice and research 111607
The difference between practice and research 111607
 
Module 1a n cov introduction v2
Module 1a  n cov introduction v2Module 1a  n cov introduction v2
Module 1a n cov introduction v2
 
Safe Injection Practices (AD Roman) - PHICS 2019
Safe Injection Practices (AD Roman) - PHICS 2019Safe Injection Practices (AD Roman) - PHICS 2019
Safe Injection Practices (AD Roman) - PHICS 2019
 
Improving Collaboration in IPC for Better Patient Outcomes (Panel discussion)...
Improving Collaboration in IPC for Better Patient Outcomes (Panel discussion)...Improving Collaboration in IPC for Better Patient Outcomes (Panel discussion)...
Improving Collaboration in IPC for Better Patient Outcomes (Panel discussion)...
 
WHO Guidelines on Core Components of Infection Prevention and Control (IPC) P...
WHO Guidelines on Core Components of Infection Prevention and Control (IPC) P...WHO Guidelines on Core Components of Infection Prevention and Control (IPC) P...
WHO Guidelines on Core Components of Infection Prevention and Control (IPC) P...
 
Operational research to increase the efficiency of ART initiation in Africa
Operational research to increase the efficiency of ART initiation in AfricaOperational research to increase the efficiency of ART initiation in Africa
Operational research to increase the efficiency of ART initiation in Africa
 
2015 pharmacoepidemiological study of menactra by meriem taib - Professor P...
2015   pharmacoepidemiological study of menactra by meriem taib - Professor P...2015   pharmacoepidemiological study of menactra by meriem taib - Professor P...
2015 pharmacoepidemiological study of menactra by meriem taib - Professor P...
 
Sponsor
SponsorSponsor
Sponsor
 
Ind by pankaj
Ind by pankajInd by pankaj
Ind by pankaj
 
Annual ed core measures.09 10
Annual ed core measures.09 10Annual ed core measures.09 10
Annual ed core measures.09 10
 
How to report an SAE
How to report an SAEHow to report an SAE
How to report an SAE
 
Patient safety and error reduction approaches
Patient safety and error reduction approachesPatient safety and error reduction approaches
Patient safety and error reduction approaches
 
National VTE Audit Day: Results and Feedback
National VTE Audit Day: Results and FeedbackNational VTE Audit Day: Results and Feedback
National VTE Audit Day: Results and Feedback
 
Role of infection control in patient safety [compatibility mode]
Role of infection control in patient safety [compatibility mode]Role of infection control in patient safety [compatibility mode]
Role of infection control in patient safety [compatibility mode]
 

Andere mochten auch

Occupatinal expolure to hiv dr. rabi
Occupatinal expolure to hiv  dr. rabiOccupatinal expolure to hiv  dr. rabi
Occupatinal expolure to hiv dr. rabiRabi Satpathy
 
Health pyschology research presentation
Health pyschology research presentationHealth pyschology research presentation
Health pyschology research presentationSrinivas Garlapati
 
Bloodborne pathogens
Bloodborne pathogensBloodborne pathogens
Bloodborne pathogensmopad10
 
Afghanistan Immunization Program
Afghanistan Immunization ProgramAfghanistan Immunization Program
Afghanistan Immunization Programcjavid2011
 
Bloodborne Pathogens And Education 2010
Bloodborne Pathogens And Education    2010Bloodborne Pathogens And Education    2010
Bloodborne Pathogens And Education 2010deborahlynneslayton
 
Occupational health & infection control
Occupational health & infection controlOccupational health & infection control
Occupational health & infection controlDr. Faisal Al Haddad
 
Workplace safety infection control
Workplace safety   infection controlWorkplace safety   infection control
Workplace safety infection controlKarim Ragab
 
Infection control disease transmission([1]
Infection control disease transmission([1]Infection control disease transmission([1]
Infection control disease transmission([1]dvernetti
 
Infection control in dentistry,dr anirudh singh chauhan
Infection control in dentistry,dr anirudh singh chauhanInfection control in dentistry,dr anirudh singh chauhan
Infection control in dentistry,dr anirudh singh chauhanAnirudh Singh Chauhan
 
2016 MOBI Immunization Update October 2016
2016 MOBI Immunization Update October 20162016 MOBI Immunization Update October 2016
2016 MOBI Immunization Update October 2016Tamara Yates
 
Immunization ready-reckoner-for-health-workers
Immunization ready-reckoner-for-health-workersImmunization ready-reckoner-for-health-workers
Immunization ready-reckoner-for-health-workersPrabir Chatterjee
 

Andere mochten auch (20)

Occupatinal expolure to hiv dr. rabi
Occupatinal expolure to hiv  dr. rabiOccupatinal expolure to hiv  dr. rabi
Occupatinal expolure to hiv dr. rabi
 
Unit 2 Transmission And Infection Control
Unit 2 Transmission And Infection ControlUnit 2 Transmission And Infection Control
Unit 2 Transmission And Infection Control
 
Health pyschology research presentation
Health pyschology research presentationHealth pyschology research presentation
Health pyschology research presentation
 
Occupational health
Occupational healthOccupational health
Occupational health
 
Routine immunization program in india
Routine immunization program in indiaRoutine immunization program in india
Routine immunization program in india
 
Bloodborne pathogens
Bloodborne pathogensBloodborne pathogens
Bloodborne pathogens
 
Medical waste managment
Medical waste managmentMedical waste managment
Medical waste managment
 
Afghanistan Immunization Program
Afghanistan Immunization ProgramAfghanistan Immunization Program
Afghanistan Immunization Program
 
Bloodborne pathogens refresh
Bloodborne pathogens refreshBloodborne pathogens refresh
Bloodborne pathogens refresh
 
Bloodborne Pathogens And Education 2010
Bloodborne Pathogens And Education    2010Bloodborne Pathogens And Education    2010
Bloodborne Pathogens And Education 2010
 
Occupational health & infection control
Occupational health & infection controlOccupational health & infection control
Occupational health & infection control
 
Occupational
OccupationalOccupational
Occupational
 
Workplace safety infection control
Workplace safety   infection controlWorkplace safety   infection control
Workplace safety infection control
 
Infection control disease transmission([1]
Infection control disease transmission([1]Infection control disease transmission([1]
Infection control disease transmission([1]
 
Infection control in dentistry,dr anirudh singh chauhan
Infection control in dentistry,dr anirudh singh chauhanInfection control in dentistry,dr anirudh singh chauhan
Infection control in dentistry,dr anirudh singh chauhan
 
Infection control latest
Infection control latestInfection control latest
Infection control latest
 
2016 MOBI Immunization Update October 2016
2016 MOBI Immunization Update October 20162016 MOBI Immunization Update October 2016
2016 MOBI Immunization Update October 2016
 
Immunization ready-reckoner-for-health-workers
Immunization ready-reckoner-for-health-workersImmunization ready-reckoner-for-health-workers
Immunization ready-reckoner-for-health-workers
 
Bbppowerpoint.ppt
Bbppowerpoint.pptBbppowerpoint.ppt
Bbppowerpoint.ppt
 
Occupational Asthma
Occupational AsthmaOccupational Asthma
Occupational Asthma
 

Ähnlich wie E R Pep Sept 2009

Post exposure prophylaxis of hiv
Post exposure prophylaxis of hivPost exposure prophylaxis of hiv
Post exposure prophylaxis of hivNiranjan Chavan
 
Management of HIV - Post-Exposure Prophylaxis Management of HIV - Post-Expo...
Management of HIV - Post-Exposure Prophylaxis 	 Management of HIV - Post-Expo...Management of HIV - Post-Exposure Prophylaxis 	 Management of HIV - Post-Expo...
Management of HIV - Post-Exposure Prophylaxis Management of HIV - Post-Expo...MedicineAndHealthUSA
 
Occupational Exposure to Blood-Borne Pathogens
Occupational Exposure to Blood-Borne PathogensOccupational Exposure to Blood-Borne Pathogens
Occupational Exposure to Blood-Borne PathogensDr. Faisal Al Haddad
 
Management of blood exposure and needle stick injuries
Management of blood exposure and needle stick injuriesManagement of blood exposure and needle stick injuries
Management of blood exposure and needle stick injuriesMoustapha Ramadan
 
www.medicotesting.com , AIDS ppt
www.medicotesting.com , AIDS pptwww.medicotesting.com , AIDS ppt
www.medicotesting.com , AIDS pptSmruti Patanaik
 
2.4 Outbreak investigation methods and application.ppt
2.4 Outbreak investigation methods and application.ppt2.4 Outbreak investigation methods and application.ppt
2.4 Outbreak investigation methods and application.pptRehmat18
 
Hematovigilance / Haemovigilance Pranav
Hematovigilance / Haemovigilance PranavHematovigilance / Haemovigilance Pranav
Hematovigilance / Haemovigilance PranavPranav S
 
HAP/VAP 2016 ATS/IDSA Guidelines. Our Data available at: https://rdcu.be/Mx8E
HAP/VAP 2016 ATS/IDSA Guidelines. Our Data available at: https://rdcu.be/Mx8EHAP/VAP 2016 ATS/IDSA Guidelines. Our Data available at: https://rdcu.be/Mx8E
HAP/VAP 2016 ATS/IDSA Guidelines. Our Data available at: https://rdcu.be/Mx8EDr Sandeep Kumar
 
ADRppt.pptx
ADRppt.pptxADRppt.pptx
ADRppt.pptxNiyasp8
 
Adverse Drug Reactions
Adverse Drug ReactionsAdverse Drug Reactions
Adverse Drug ReactionsKajal Rajdev
 
stakeholders in IPC.pptx
stakeholders in IPC.pptxstakeholders in IPC.pptx
stakeholders in IPC.pptxNehaPandey199
 

Ähnlich wie E R Pep Sept 2009 (20)

Management of occup exposures
Management of occup exposuresManagement of occup exposures
Management of occup exposures
 
Post exposure prophylaxis of hiv
Post exposure prophylaxis of hivPost exposure prophylaxis of hiv
Post exposure prophylaxis of hiv
 
Management of HIV - Post-Exposure Prophylaxis Management of HIV - Post-Expo...
Management of HIV - Post-Exposure Prophylaxis 	 Management of HIV - Post-Expo...Management of HIV - Post-Exposure Prophylaxis 	 Management of HIV - Post-Expo...
Management of HIV - Post-Exposure Prophylaxis Management of HIV - Post-Expo...
 
The HIV Prevention–Certified Provider Program: A Training and Certificate Pro...
The HIV Prevention–Certified Provider Program: A Training and Certificate Pro...The HIV Prevention–Certified Provider Program: A Training and Certificate Pro...
The HIV Prevention–Certified Provider Program: A Training and Certificate Pro...
 
Occupational Exposure to Blood-Borne Pathogens
Occupational Exposure to Blood-Borne PathogensOccupational Exposure to Blood-Borne Pathogens
Occupational Exposure to Blood-Borne Pathogens
 
NYSDOH AI PrEP for HIV Prevention
NYSDOH AI PrEP for HIV PreventionNYSDOH AI PrEP for HIV Prevention
NYSDOH AI PrEP for HIV Prevention
 
Management of blood exposure and needle stick injuries
Management of blood exposure and needle stick injuriesManagement of blood exposure and needle stick injuries
Management of blood exposure and needle stick injuries
 
6. pep
6. pep6. pep
6. pep
 
www.medicotesting.com , AIDS ppt
www.medicotesting.com , AIDS pptwww.medicotesting.com , AIDS ppt
www.medicotesting.com , AIDS ppt
 
PEP for HIV
PEP for HIV PEP for HIV
PEP for HIV
 
11915935.ppt
11915935.ppt11915935.ppt
11915935.ppt
 
2.4 Outbreak investigation methods and application.ppt
2.4 Outbreak investigation methods and application.ppt2.4 Outbreak investigation methods and application.ppt
2.4 Outbreak investigation methods and application.ppt
 
Truvada kaletra o raltegravir pr ep
Truvada kaletra o raltegravir pr epTruvada kaletra o raltegravir pr ep
Truvada kaletra o raltegravir pr ep
 
Hematovigilance / Haemovigilance Pranav
Hematovigilance / Haemovigilance PranavHematovigilance / Haemovigilance Pranav
Hematovigilance / Haemovigilance Pranav
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
 
HAP/VAP 2016 ATS/IDSA Guidelines. Our Data available at: https://rdcu.be/Mx8E
HAP/VAP 2016 ATS/IDSA Guidelines. Our Data available at: https://rdcu.be/Mx8EHAP/VAP 2016 ATS/IDSA Guidelines. Our Data available at: https://rdcu.be/Mx8E
HAP/VAP 2016 ATS/IDSA Guidelines. Our Data available at: https://rdcu.be/Mx8E
 
ADRppt.pptx
ADRppt.pptxADRppt.pptx
ADRppt.pptx
 
Adverse Drug Reactions
Adverse Drug ReactionsAdverse Drug Reactions
Adverse Drug Reactions
 
stakeholders in IPC.pptx
stakeholders in IPC.pptxstakeholders in IPC.pptx
stakeholders in IPC.pptx
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
 

E R Pep Sept 2009

  • 1. Guideline Summary Updated US Public Health Service Guidelines for the Management of Occupational Exposures to HIV and Recommendations for Postexposure Prophylaxis
  • 2. Guidelines for the Management of Occupational Exposures to HIV and Recommendations for Postexposure Prophylaxis Developed by the Public Health Service Interagency Working Group, convened by National Center for Infectious Diseases, CDC
  • 3.
  • 4.
  • 5.
  • 6.
  • 7.
  • 8.
  • 9. PEP after Occupational Exposure http://www.hivguidelines.org/GuideLine.aspx?pageID=78&guideLineID=3
  • 10.
  • 11.
  • 12.
  • 13.
  • 14.  
  • 15.
  • 16.
  • 17.
  • 18.
  • 19.
  • 20.
  • 21.
  • 22.
  • 23.
  • 24.
  • 25.
  • 26.
  • 27. NY AIDS inst recommended PEP www.hivguidelines.org
  • 28.
  • 29.  
  • 30.
  • 31.
  • 32.  
  • 33.
  • 34.
  • 35.
  • 36.
  • 37.
  • 38.
  • 39.
  • 40.
  • 41.  
  • 42.
  • 43.
  • 44. PEP for Percutaneous Injuries Exposure Type Infection Status of Source Recommend expanded ≥ 3-drug PEP Recommend expanded 3-drug PEP More severe Recommend expanded ≥ 3-drug PEP Recommend basic 2-drug PEP Less severe HIV+, class 2 HIV+, class 1
  • 45. PEP for Percutaneous Injuries (2) Exposure Type Infection Status of Source *If PEP is given and source is later determined to be HIV negative, PEP should be discontinued. As above Generally, no PEP warranted; consider basic 2-drug PEP if exposure to HIV-infected persons is likely Unknown source As above More severe Generally, no PEP warranted; consider basic 2-drug PEP if source has HIV risk factors Less severe Unknown HIV status*
  • 46. PEP for Percutaneous Injuries (3) Exposure Type Infection Status of Source No PEP More severe No PEP Less severe HIV negative
  • 47. PEP for Mucous Membrane and Nonintact Skin Exposures Exposure Type Infection Status of Source Recommend expanded ≥ 3-drug PEP Recommend basic 2-drug PEP More severe Recommend basic 2-drug PEP Consider basic 2-drug PEP Less severe HIV+, class 2 HIV+, class 1
  • 48. PEP for Mucous Membrane and Nonintact Skin Exposures (2) Exposure Type Infection Status of Source *If source is determined to be HIV negative after PEP is initiated, discontinue PEP. Generally, no PEP warranted; consider basic 2-drug PEP if exposure to HIV-infected persons is likely Generally, no PEP warranted Unknown source Generally, no PEP warranted; consider basic 2-drug PEP if source has HIV risk factors More severe Generally, no PEP warranted Less severe Unknown HIV status*
  • 49. PEP for Mucous Membrane and Nonintact Skin Exposures (3) Exposure Type Infection Status of Source No PEP More severe No PEP Less severe HIV negative
  • 50.
  • 51.
  • 52.
  • 53.
  • 54.
  • 55.
  • 56.
  • 57.
  • 58.
  • 59.
  • 60.
  • 61. About This Presentation These slides were developed using the September 2005 guidelines on postexposure prophylaxis (PEP) following occupational exposure to HIV. The intended audience is clinicians involved in the care of health care personnel (HCP) with occupational exposure to HIV. Users are cautioned that, because of the rapidly changing field of HIV care, this information could become out of date quickly. Finally, it is intended that these slides be used as prepared, without changes in either content or attribution. Users are asked to honor this intent. – AETC NRC http://www.aidsetc.org